3D Medicines to Replace Hong Kong Process Agent and Move Principal Office Effective 4 August 2026
Bulletin Express
Aug 04
3D Medicines Inc. announced two administrative changes that will take effect on 4 August 2026.
First, the company has appointed Ms. Leung Ching Ching as its new agent for the acceptance of service of process and notices in Hong Kong under Part 16 of the Companies Ordinance, replacing Ms. Li Ching Yi.
Second, the company’s principal place of business in Hong Kong will relocate to 16/F, Wing On Centre, 111 Connaught Road Central, Hong Kong on the same effective date.
The decision was approved by the board of directors, currently chaired by Dr. Gong Zhaolong and comprising one executive director, three non-executive directors, and three independent non-executive directors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.